Kingsview Wealth Management LLC Reduces Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Kingsview Wealth Management LLC lessened its stake in Novo Nordisk A/S (NYSE:NVO) by 14.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,266 shares of the company’s stock after selling 378 shares during the quarter. Kingsview Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $234,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Pacific Center for Financial Services boosted its stake in shares of Novo Nordisk A/S by 100.0% in the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after purchasing an additional 135 shares during the period. Bell Investment Advisors Inc increased its stake in Novo Nordisk A/S by 79.9% during the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock worth $26,000 after buying an additional 127 shares during the period. CNB Bank acquired a new position in Novo Nordisk A/S in the 4th quarter worth $26,000. Tyler Stone Wealth Management boosted its position in Novo Nordisk A/S by 100.0% in the 3rd quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock valued at $27,000 after buying an additional 146 shares during the last quarter. Finally, West Paces Advisors Inc. grew its stake in shares of Novo Nordisk A/S by 100.0% during the third quarter. West Paces Advisors Inc. now owns 300 shares of the company’s stock valued at $27,000 after acquiring an additional 150 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 0.8 %

Shares of Novo Nordisk A/S stock opened at $134.09 on Thursday. The business has a 50-day moving average price of $128.11 and a 200 day moving average price of $116.07. Novo Nordisk A/S has a fifty-two week low of $75.56 and a fifty-two week high of $138.28. The firm has a market cap of $601.73 billion, a P/E ratio of 46.24, a P/E/G ratio of 1.39 and a beta of 0.43. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17.

Wall Street Analyst Weigh In

Several research firms recently commented on NVO. BMO Capital Markets assumed coverage on Novo Nordisk A/S in a research note on Friday, April 12th. They issued an “outperform” rating and a $163.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and a consensus price target of $133.60.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.